Valencia Technologies Secures $35M Funding and Appoints Industry Veteran Jim Surek as CEO to Accelerate Commercialization of eCoin®, the First FDA-Approved Implantable Tibial Nerve Stimulator for Urge Urinary Incontinence

Feb 20, 2025 22:15 CST Updated 22:15

Valencia Technologies

Developer of Implantable Neurostimulation Devices

Valencia TechnologiesAnnounced the completion of up to $35 million in financing, led byInvestment by Brooks Management Group (BMG). This round of financing will be used to accelerate its core products.eCoinCommercialization,eCoinApproved by the FDA for market release in 2022, it is also the first tibial nerve stimulator approved by the FDA.

Valencia TechnologiesIn addition to completing the financing round, a new CEO was also brought on board---Jim Surek。Jim SurekPreviously worked at Boston Scientific and Medtronic, and led Advanced Bionics, a cochlear implant company, to grow its sales from $68 million to over $200 million within three years, ultimately resulting in its acquisition by Boston Scientific for $3 billion. Additionally, guided Entellus Medical to expand its sales from $1 million to $70 million, leading to its acquisition by Stryker for $660 million.

Jim Surek's addition will enableValencia TechnologiesSmoother commercialization path, also poised to disruptSacral Nerve Stimulation for the Treatment of Urinary Incontinence (Sacral NerveToo many stimulation-related complications). Thus, allowingPatients with overactive bladder (OAB) can receive treatment with more advanced technologies.

Investor Evaluation

“BMG has a successful track record in investing in technologies such as eCoin, precisely because of our firm’s deep involvement with its portfolio companies. Jim Surek is the premier leader in the commercialization of medical devices, second to none. BMG is pleased that Jim has taken on the role”As the CEO of Valencia Technologies, we believe he will achieve success in his distinguished career.”

---Ryan Brooks Managing Partner, BMG

Expert Evaluation

“Many patients with overactive bladder, burdened by embarrassment and anxiety, desire an alternative to expensive medications and other more complex treatments. With eCoin, I can offer an effective alternative for patients with urge urinary incontinence—requiring only a single procedure, after which patients generally no longer need hospital visits.”

---Jason Kim Stony Brook Medicine

eCoin

eCoinis a revolutionary leadlesstibial nerve stimulator, used to address issues due toOveractive Bladder（OAB）Induced urinary urgency and incontinence issues.

eCoinmore than one Chinese yuan (Diameter: 25 mm) Small, can be implanted in an outpatient setting (only local anesthesia required).eCoinThe internal structure is also very “simple,” containing a battery and a chip. Once implanted, it automatically delivers intermittent stimulation to the tibial nerve, helping to alleviate symptoms of UUI.

Compared with traditionalSacral Nerve StimulatorIn comparison,eCoinThe procedure has become simple and reliable. Due toeCoinLeadless Design, Addressing Traditional ProductsPrecise insertion of the fragile lead through the epidermis to the treatment area is required, with nerveUpon coordination.ObtainandeCoinThe surgery is much simpler, requiring onlyeCoinImplanted above the tibial nerve at the ankle, its broad dome-shaped stimulation field delivers conventional stimulation to the nerve to stabilize the bladder and alleviate bladder leakage. MeanwhileeCoinAfter implantation, it is difficult to detect, ensuring patient privacy.

eCoin Clinical

eCoinA prospective, single-arm, multicenter trial was completed prior to market launch to validate the safety and efficacy of eCoin in the treatment of overactive bladder—the Valencia study. The Valencia study enrolled 133 patients, all of whom were followed up for up to 12 months postoperatively. All study subjects suffered fromOveractive Bladder (OAB)with urgency urinary incontinence (UUI), having tried at least one second- or third-line treatment for overactive bladder (OAB), and remaining off OAB medications throughout the study period.

Research Results Show

50% of patients experienced at least a 50% reduction in urgency urinary incontinence (UUI) episodes. 81% of patients reported feeling “much better” or “very much better” one year after the procedure. According toValencia TechnologiesIntroduction, implantationeCoinThe patient believes it is aAn excellent experience, with 97% of patients reporting that they were fully informedeCoinImplantation Process: 89% of Patients Indicated They Would Recommend It to Friends or FamilyeCoin。

eCoin Demo

Valencia Technologies

Valencia Technologiesis a company located in Valencia, CaliforniaValencia Technologies Corporation, dedicated to improving the standard of care for bladder dysfunction. ItsDesigned and manufactured the eCoin® device for the treatment of urgency urinary incontinence (UUI).